Preventive Genomics: Risk Prediction and Personalized Preventive Care

Farah Maizie*

Department of Life Sciences, Bar-Ilan University, Ramat Gan 5290000, Israel

*Corresponding author: Farah Maizie, Department of Life Sciences, Bar-Ilan University, Ramat Gan 5290000, Israel, E-mail: Maizie.farah@gmail.com

Citation: Maizie F (2025) Preventive Genomics: Risk Prediction and Personalized Preventive Care. J Prev Med Vol.10 No.1: 274.

Introduction

The rise of genomic science has revolutionized the landscape of modern medicine, offering unprecedented opportunities to shift healthcare from reactive treatment to proactive prevention. Preventive genomics refers to the use of genomic information to assess an individual's risk of developing specific diseases before symptoms arise. This approach allows for early intervention, tailored preventive strategies, and more informed clinical decision-making. As genome sequencing becomes more accessible and affordable, preventive genomics is rapidly becoming an integral part of personalized healthcare. With the ability to identify genetic predispositions, healthcare providers can move beyond general recommendations and offer personalized preventive care that aligns with an individual's unique genetic profile [1].

Description

Preventive genomics is grounded in the understanding that genetic variations can significantly influence an individual's susceptibility to a wide range of conditions, including cancer, cardiovascular diseases, neurodegenerative disorders and metabolic syndromes. Advances in genomics have identified numerous genetic markers Single Nucleotide Polymorphisms (SNPs), gene mutations and structural variations that contribute to disease risk. This knowledge enables the development of risk prediction models that estimate an individual's probability of developing a condition over a lifetime or within a certain time frame. One of the earliest and most well-known applications of preventive genomics is in hereditary breast and ovarian cancer. Individuals who carry BRCA1 or BRCA2 gene mutations face significantly higher risks of developing these cancers. Identifying such mutations through genetic testing enables clinicians to recommend enhanced screening, risk-reducing medications, or even prophylactic surgery to prevent disease onset.

Similarly, genomic testing can reveal risks for conditions like Lynch syndrome, familial hypercholesterolemia and hereditary colon cancer, allowing for earlier and more aggressive preventive measures. Beyond Monogenic (single-gene) disorders, preventive genomics also encompasses Polygenic Risk Scores (PRS), which aggregate the effects of many genetic variants across the genome. These scores are particularly useful for common, multifactorial diseases such as type 2 diabetes, coronary artery disease and hypertension. By combining PRS with other clinical and lifestyle factors, clinicians can stratify individuals into different risk categories and customize preventive strategies accordingly. For instance, a person with a high polygenic risk for coronary artery disease may benefit from more frequent cardiovascular screening, stricter lipid management and earlier lifestyle interventions than someone at average risk. Pharmacogenomics, another application of preventive genomics, evaluates how genetic variations affect an individual's response to medications. This information can help avoid adverse drug reactions and improve treatment efficacy by guiding drug selection and dosing. For example, certain genetic variants in the CYP450 enzymes can influence how individuals metabolize drugs like warfarin or clopidogrel, which are commonly prescribed for cardiovascular conditions. By integrating pharmacogenomic data into electronic health records, clinicians can make safer and more effective prescribing decisions, thus preventing complications before they arise. Preventive genomics also has a role in reproductive planning. Carrier screening can identify couples at risk of passing on inherited genetic disorders such as cystic fibrosis, Tay-Sachs disease, or sickle cell anemia. Preconception or prenatal genetic testing allows for informed reproductive choices, early diagnosis and intervention when necessary. One of the key advantages of preventive genomics is the opportunity for early lifestyle and behavioral interventions. While genetic predisposition plays a significant role in disease development, environmental factors, including diet, physical activity, stress and exposure to toxins, also contribute substantially [2].

Knowledge of genetic risk can motivate individuals to adopt healthier behaviors. For instance, individuals with a genetic predisposition to obesity or diabetes may be more inclined to follow personalized nutrition and fitness plans to mitigate their risk. Similarly, those at increased risk for melanoma can be encouraged to undergo routine skin examinations and adopt rigorous sun protection habits. However, the integration of preventive genomics into routine care requires a comprehensive and multidisciplinary approach. Healthcare providers must be trained to interpret and communicate genomic information effectively. Genetic counsellors play a critical role in guiding patients through complex genetic data, addressing emotional concerns and ensuring informed decision-making. It is essential to provide individuals with not just test results, but also context, education and support to translate genomic insights into actionable health strategies. Data privacy and ethical considerations also arise in the context of preventive genomics. Genomic data is highly personal and potentially sensitive. Ensuring confidentiality, preventing discrimination (e.g., by employers or insurers) and obtaining informed consent are foundational principles in genomic medicine. Laws such as the Genetic Information Nondiscrimination Act (GINA) in the United States offer some protection, but global standards and frameworks are still evolving. Additionally, questions remain about how to handle incidental findings genetic variants that are unrelated to the primary reason for testing but may carry health implications. Equity in access is another critical concern. While genomic technologies are becoming more affordable, disparities persist in who can benefit from them. Ensuring that preventive genomics reaches diverse populations across socio-economic, geographic and ethnic backgrounds is vital to avoid deepening existing health inequities. Representation in genomic research must also be improved, as current polygenic risk models are often based on data from predominantly European populations, limiting their accuracy in other ethnic groups.

Conclusion

Preventive genomics represents a transformative shift in healthcare, moving from a reactive model to one focused on risk prediction and early intervention. By leveraging genetic insights, clinicians and patients can work together to develop personalized preventive care strategies that address individual risks before disease develops. This proactive approach has the potential to reduce the incidence and burden of chronic conditions, improve quality of life and make healthcare more efficient and precise. However, for preventive genomics to realize its full potential, it must be implemented thoughtfully ensuring data privacy, ethical integrity, provider training and equitable access for all populations. As technology continues to evolve and our understanding of the human genome deepens, preventive genomics will play an increasingly central role in shaping the future of personalized, predictive and preventive healthcare.

Acknowledgement

Conflict of Interest

None.

References

1. Voidăzan TS, Budianu MA, Rozsnyai FF, Kovacs Z, Uzun CC, et al. (2022) Assessing the level of knowledge, beliefs and acceptance of HPV vaccine: A cross-sectional study in Romania. Int J Environ Res Public Health 19: 6939.

2. El Mansouri N, Ferrera L, Kharbach A, Achbani A, Kassidi F, et al. (2022) Awareness and knowledge associated to human papillomavirus infection among university students in Morocco: A cross-sectional study. PLoS One 17: e0271222.